Long-Term Outcomes of Medicare Beneficiaries With Worsening Renal Function During Hospitalization for Heart Failure

American Journal of Cardiology

Volumn 105, Issue 12, 2010, Pages 1786-1793

  Kociol, Robb D ^a,b   Greiner, Melissa A ^a   Hammill, Bradley G ^a   Phatak, Hemant ^c   Fonarow, Gregg C ^d   Curtis, Lesley H ^a,b   Hernandez, Adrian F ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGED; ARTICLE; CLINICAL EVALUATION; COMORBIDITY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; HAZARD RATIO; HEART FAILURE; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEALTH CARE COSTS; HEART FAILURE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MEDICARE; PROGNOSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; UNITED STATES;

EID: 77953119806     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.01.361     Document Type: Article

References (29)

1. Ferguson D.W., Berg W.J., Roach P.J., Oren R.M., and Mark A.L. Effects of heart failure on baroreflex control of sympathetic neural activity. Am J Cardiol 69 (1992) 523-531
2. Schrier R.W., and Abraham W.T. Hormones and hemodynamics in heart failure. N Engl J Med 341 (1999) 577-585
3. Francis G.S., Siegel R.M., Goldsmith S.R., Olivari M.T., Levine T.B., and Cohn J.N. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 103 (1985) 1-6
4. Dries D.L., Sweitzer N.K., Drazner M.H., Stevenson L.W., and Gersh B.J. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35 (2000) 681-689
5. Forman D.E., Butler J., Wang Y., Abraham W.T., O'Connor C.M., Gottlieb S.S., Loh E., Massie B.M., Rich M.W., Stevenson L.W., Young J.B., and Krumholz H.M. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 43 (2004) 61-67
6. Hillege H.L., Nitsch D., Pfeffer M.A., Swedberg K., McMurray J.J., Yusuf S., Granger C.B., Michelson E.L., Ostergren J., Cornel J.H., de Zeeuw D., Pocock S., van Veldhuisen D.J., and Candesartan in Heart Failure: Assessment of Reduction In Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113 (2006) 671-678
7. Nohria A., Hasselblad V., Stebbins A., Pauly D.F., Fonarow G.C., Shah M., Yancy C.W., Califf R.M., Stevenson L.W., and Hill J.A. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 51 (2008) 1268-1274
8. Weinfeld M.S., Chertow G.M., and Stevenson L.W. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 138 (1999) 285-290
9. Fonarow G.C., Abraham W.T., Albert N.M., Gattis W.A., Gheorghiade M., Greenberg B., O'Connor C.M., Yancy C.W., and Young J. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J 148 (2004) 43-51
10. Fonarow G.C., Lukas M.A., Robertson M., Colucci W.S., and Dargie H.J. Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN). Am Heart J 154 (2007) 637-644
11. Curtis L.H., Greiner M.A., Hammill B.G., DiMartino L.D., Shea A.M., Hernandez A.F., and Fonarow G.C. Representativeness of a national heart failure quality-of-care registry: comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients. Circ Cardiovasc Qual Outcomes 2 (2009) 377-384
12. Hammill B.G., Hernandez A.G., Peterson E.D., Fonarow G.C., Schulman K.A., and Curtis L.H. Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J 157 (2009) 995-1000
13. Krumholz H.M., Chen Y.T., Vaccarino V., Wang Y., Radford M.J., Bradford W.D., and Horwitz R.I. Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. Am J Cardiol 85 (2000) 1110-1113
14. Damman K., Navis G., Voors A.A., Asselbergs F.W., Smilde T.D., Cleland J.G., van Veldhuisen D.J., and Hillege H.L. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 13 (2007) 599-608
15. Prentice R.L., Kalbfleisch J.D., Peterson Jr. A.V., Flournoy N., Farewell V.T., and Breslow N.E. The analysis of failure times in the presence of competing risks. Biometrics 34 (1978) 541-554
16. Lin D.Y., and Wei L.J. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 84 (1989) 1074-1078
17. Krumholz H.M., Parent E.M., Tu N., Vaccarino V., Wang Y., Radford M.J., and Hennen J. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 157 (1997) 99-104
18. Smith G.L., Lichtman J.H., Bracken M.B., Shlipak M.G., Phillips C.O., DiCapua P., and Krumholz H.M. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 47 (2006) 1987-1996
19. Abraham W.T., Fonarow G.C., Albert N.M., Stough W.G., Gheorghiade M., Greenberg B.H., O'Connor C.M., Sun J.L., Yancy C.W., Young J.B., and OPTIMIZE-HF Investigators and Coordinators. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 52 (2008) 347-356
20. Heywood J.T., Fonarow G.C., Costanzo M.R., Mathur V.S., Wigneswaran J.R., Wynne J., and ADHERE Scientific Advisory Committee and Investigators. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 13 (2007) 422-430
21. Hillege H.L., Girbes A.R., de Kam P.J., Boomsma F., de Zeeuw D., Charlesworth A., Hampton J.R., and van Veldhuisen D.J. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102 (2000) 203-210
22. Butler J., Geisberg C., Howser R., Portner P.M., Rogers J.G., Deng M.C., and Pierson III R.N. Relationship between renal function and left ventricular assist device use. Ann Thorac Surg 81 (2006) 1745-1751
23. Smilde T.D., van Veldhuisen D.J., Navis G., Voors A.A., and Hillege H.L. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 114 (2006) 1572-1580
24. Shlipak M.G., Sarnak M.J., Katz R., Fried L.F., Seliger S.L., Newman A.B., Siscovick D.S., and Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352 (2005) 2049-2060
25. Lassus J., Harjola V.P., Sund R., Siirilä-Waris K., Melin J., Peuhkurinen K., Pulkki K., Nieminen M.S., and FINN-AKVA Study Group. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 28 (2007) 1841-1847
26. Bennett M., Dent C.L., Ma Q., Dastrala S., Grenier F., Workman R., Syed H., Ali S., Barasch J., and Devarajan P. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 3 (2008) 665-673
27. Bonventre J.V. Kidney injury molecule-1 (KIM-1): a specific and sensitive biomarker of kidney injury. Scand J Clin Lab Invest Suppl 241 (2008) 78-83
28. Damman K., van Veldhuisen D.J., Navis G., Voors A.A., and Hillege H.L. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 10 (2008) 997-1000
29. Mishra J., Dent C., Tarabishi R., Mitsnefes M.M., Ma Q., Kelly C., Ruff S.M., Zahedi K., Shao M., Bean J., Mori K., Barasch J., and Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365 (2005) 1231-1238